This website uses cookies to ensure the best possible functionality and user experience. To consent to our use of cookies please click "Accept Cookies."

10 Years of Excellence

Ten years of innovation, collaboration and a shared commitment to improving patient care has shaped Zai Lab into a fully integrated and innovative global biopharmaceutical company. Since its founding in 2014, Zai has focused on developing and commercializing innovative therapies that deliver meaningful outcomes to patients around the world.

We have always been mindful that there are no borders when it comes to innovation and patient needs. Over the past 10 years Zai Lab has rapidly built up a pipeline of potential first-in-class and/or best-in-class late-stage therapies, successfully developing and commercializing several therapies in China. Simultaneously, Zai has been actively invested in internal R&D initiatives, with several early-stage programs underway.

Over the next 10 years we will leverage our strengths and proven track record to continue to innovate and meet our commitment to patients. Anchored by our dedication to scientific excellence and uncompromising quality, our goal is to reach 1-million patients by 2030. We are committed to powering the future of global health.

Message from the Founder and CEO

“After a decade of growth and innovation Zai Lab stands on a solid foundation, ready to embark on its next chapter. We will continue to embrace our spirit of scientific entrepreneurship, being resilient in the face of challenges and continuing to look for new and better ways to meet patient needs. By focusing on innovative and differentiated therapies, we will continue to fill critical gaps in the therapeutic landscape to make a positive impact on patients’ lives.”

Samantha Du, Ph.D.
Founder, Chairperson and Chief Executive Officer

Quotes

Milestones

July 2024
China NMPA approved the BLA for efgartigimod alfa injection (subcutaneous injection) for patients with generalized myasthenia gravis
May 2024
China NMPA approved XACDURO® for the treatment of hospital-acquired and ventilator-associated pneumonia caused by acinetobacter baumannii-calcoaceticus complex
May 2024
China NMPA approved AUGTYRO™ for the treatment of ROS1-positive NSCLC
June 2023
China NMPA approved the BLA for VYVGART® (efgartigimod alfa injection, intravenous) for patients with generalized myasthenia gravis
June 2022
Completed the conversion to a primary listing on the Main Board of Hong Kong Stock Exchange
December 2021
China NMPA approved Nuzyra® for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
September 2021
Opened office in Cambridge, Massachusetts, US
May 2021
Opened office in Taiwan (China)
April 2021
Completed $858 million global follow-on offering
March 2021
China NMPA approved QINLOCK® for fourth-line treatment of advanced gastrointestinal stromal tumors
September 2020
Completed HK$5.94 billion ($881 million) secondary listing on Hong Kong Stock Exchange
September 2020
China NMPA approved ZEJULA® for first-line maintenance treatment of ovarian cancer
May 2020
China NMPA approved OPTUNE GIO® for the treatment of newly diagnosed and recurrent glioblastoma
January 2020
Completed $299 million NASDAQ follow-on offering
December 2019
China NMPA approved ZEJULA® as maintenance therapy for recurrent ovarian cancer
June 2019
Opened office in Beijing, China
May 2019
Completed $200 million NASDAQ follow-on offering
December 2018
Launched OPTUNE GIO® in Hong Kong (China)
December 2018
Launched ZEJULA® in Hong Kong (China)
September 2018
Completed $150 million NASDAQ follow-on offering
August 2018
Opened office in Hong Kong (China)
June 2018
Completed construction of large-molecule manufacturing facility in Suzhou, China
September 2017
Completed $172 million NASDAQ IPO
September 2017
Completed construction of small-molecule commercial manufacturing facility in Suzhou, China
May 2017
Launched new global R&D center in Shanghai, China
January 2016
Completed $106 million series B financing
October 2015
Opened R&D center in Shanghai, China
August 2014
Completed $30 million in series A financing
March 2014
Established Zai Lab